Innovotech Inc  

(Public, CVE:IOT)   Watch this stock  
Find more results for IOT
0.0500
0.0000 (0.00%)
Delayed:   9:32AM EDT
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 0.03 - 0.28
Open     -
Vol / Avg. 0.00/4,803.00
Mkt cap 1.44M
P/E     -
Div/yield     -
EPS -0.03
Shares 28.74M
Beta -0.08
Inst. own     -

Key stats and ratios

Q3 (Sep '13) 2012
Net profit margin -117.81% -172.43%
Operating margin -109.48% -166.89%
EBITD margin - -159.77%
Return on average assets -134.85% -137.64%
Return on average equity - -424.21%
Employees 16 -
CDP Score - -

Address

Suite 101, 2011-94 Street
EDMONTON, AB T6N 1H1
Canada
+1-780-4480585 (Phone)
+1-780-4240941 (Fax)

Website links

Description

Innovotech Inc. (Innovotech) is a biofilm product development, focused on providing solutions to medical, agricultural and industrial problems caused by microbial biofilms. Its products include human and veterinary biofilm susceptibility tests, a seed treatment designed to combat both bacterial and fungal diseases, and an assay used in growing microbial biofilms for research purposes. Innovotech has a range of products, which include commercially available products in three market segments: the MBEC Assay, bioFILM PA and the InnovoSCEPT veterinary tests for the research and development market, human health and veterinary markets respectively; and three products in advanced stages of development: the InnovoSCEPT human tests, Agress and Sani-Lux. The MBEC Assay is a throughput biofilm growth device. bioFILM PA is for treatment of patients with Pseudomonas aeruginosa infections. Innovotech has a pipeline of products targeting biofilm issues, including a second silver product, AgreGuard.

Officers and directors

James Timourian Ph.D. Chairman of the Board, President, Chief Financial Officer
Bruce Darryl Hirsche Q.C. Corporate Secretary, Director
Age: 66
Bernard Grobbelaar Director
Robert Huizinga Director
Wolfgang H. Muhs Ph.D. Independent Director
Gerard Tertzakian Ph.D. Independent Director